Entering text into the input field will update the search result below

Myovant Sciences rejects Sumitovant Biopharma's $2.4 billion takeover offer

Oct. 02, 2022 8:33 PM ETMyovant Sciences Ltd. (MYOV)PFEBy: Joshua Fineman, SA News Editor3 Comments

word m and a made with wood building blocks, stock image

Maksim Labkouski

Myovant Sciences (NYSE:MYOV) said a special committee of its board rejected a $2.4 billion, or $22.75/share, offer from Sumitovant Biopharma to buy the remaining shares of the biopharma company it doesn't already own.

Sumitovant currently holds approximately 52% of

Recommended For You

Comments (3)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

6 billion MC minimum. 3 approved drugs. Unbelievable
Et20 profile picture

I think its the same compound but 3 indications.
Whoa! Dave is playing hard ball! The Endo approval should result in a much higher premium. I’d like to see PFE step in now with all that COVID money and make a real offer. This company is worth more than $50!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.